These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 21138519)

  • 21. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
    Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
    Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of high-protein meals during hemodialysis combined with lanthanum carbonate in hypoalbuminemic dialysis patients: findings from the FrEDI randomized controlled trial.
    Rhee CM; You AS; Koontz Parsons T; Tortorici AR; Bross R; St-Jules DE; Jing J; Lee ML; Benner D; Kovesdy CP; Mehrotra R; Kopple JD; Kalantar-Zadeh K
    Nephrol Dial Transplant; 2017 Jul; 32(7):1233-1243. PubMed ID: 27659126
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Lanthanum carbonate in clinical practice].
    Torregrosa Prats V
    Nefrologia; 2008; 28 Suppl 5():11-4. PubMed ID: 18847414
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of calcium carbonate combined with calcitonin on hypercalcemia in hemodialysis patients.
    Wei Y; Kong XL; Li WB; Wang ZS
    Ther Apher Dial; 2014 Dec; 18(6):618-22. PubMed ID: 24674384
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lanthanum carbonate is an effective hypophosphatemic agent for hemodialysis patients intolerant of other phosphate binders.
    Chan WL; Rounsley K; Chapman E; Collings K; Dale C; De Waal S; Patel V; Tanner J; Turner E; Moore J; Borrows R
    J Ren Nutr; 2010 Jul; 20(4):270-7. PubMed ID: 20362463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lanthanum carbonate: a postmarketing observational study of efficacy and safety.
    Rombolà G; Londrino F; Corbani V; Falqui V; Ardini M; Zattera T;
    J Nephrol; 2012; 25(4):490-6. PubMed ID: 22476966
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of lanthanum carbonate and calcium carbonate on fibroblast growth factor 23 and hepcidin levels in chronic hemodialysis patients.
    Chang YM; Tsai SC; Shiao CC; Liou HH; Yang CL; Tung NY; Hsu KS; Chen IL; Liu MC; Kao JL; Jhen RN; Huang YT
    Clin Exp Nephrol; 2017 Oct; 21(5):908-916. PubMed ID: 27928636
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients.
    D'Haese PC; Spasovski GB; Sikole A; Hutchison A; Freemont TJ; Sulkova S; Swanepoel C; Pejanovic S; Djukanovic L; Balducci A; Coen G; Sulowicz W; Ferreira A; Torres A; Curic S; Popovic M; Dimkovic N; De Broe ME
    Kidney Int Suppl; 2003 Jun; (85):S73-8. PubMed ID: 12753271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy evaluation of lanthanum carbonate for hyperphosphatemia in end-stage renal disease patients.
    Shigematsu T; Ohya M; Negi S; Masumoto AR; Nakashima YM; Iwatani Y; Moribata MK; Yamanaka S; Tatsuta K; Mima T
    Contrib Nephrol; 2015; 185():42-55. PubMed ID: 26023014
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate.
    Hutchison AJ; Speake M; Al-Baaj F
    Nephrol Dial Transplant; 2004 Jul; 19(7):1902-6. PubMed ID: 15199195
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lanthanum carbonate.
    Swainston Harrison T; Scott LJ
    Drugs; 2004; 64(9):985-96; discussion 997-8. PubMed ID: 15101790
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
    Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
    [TBL] [Abstract][Full Text] [Related]  

  • 33. One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis.
    Shigematsu T;
    Ther Apher Dial; 2010 Feb; 14(1):12-9. PubMed ID: 20438515
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nicotinamide suppresses hyperphosphatemia in hemodialysis patients.
    Takahashi Y; Tanaka A; Nakamura T; Fukuwatari T; Shibata K; Shimada N; Ebihara I; Koide H
    Kidney Int; 2004 Mar; 65(3):1099-104. PubMed ID: 14871431
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The real-world dose-relativity of sevelamer hydrochloride and lanthanum carbonate monotherapy in patients with end-stage renal disease.
    Wilson RJ; Keith MS; Preston P; Copley JB
    Adv Ther; 2013 Dec; 30(12):1100-10. PubMed ID: 24307220
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate.
    Hutchison AJ; Maes B; Vanwalleghem J; Asmus G; Mohamed E; Schmieder R; Backs W; Jamar R; Vosskuhler A
    Nephron Clin Pract; 2005; 100(1):c8-19. PubMed ID: 15809508
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical effects of long-term (36-month) lanthanum carbonate administration in hemodialysis patients in Japan.
    Kishi Y; Obara Y; Hara K; Yamashiro H; Kurosawa N; Takada D
    Ther Apher Dial; 2014 Jun; 18 Suppl 1():9-13. PubMed ID: 24953760
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Three-year follow-up of lanthanum carbonate therapy in hemodialysis patients.
    Takeuchi K; Matsuda E; Sekino M; Hasegawa Y; Kamo Y; Kikuchi N; Sekino H
    Ther Apher Dial; 2013 Apr; 17 Suppl 1():15-21. PubMed ID: 23586508
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RenaGel efficacy in severe secondary hyperparathyroidism.
    Castro R; Herman A; Ferreira C; Travassos F; Nunes-Azevedo J; Oliveira M
    Nefrologia; 2002; 22(5):448-55. PubMed ID: 12497746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lanthanum carbonate provides control of phosphorus levels in patients new to phosphate binder therapy and patients changed from other phosphate binders.
    Noto L
    J Ren Nutr; 2011 May; 21(3):277-82. PubMed ID: 20598905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.